Péptidos

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF529 antibody, catalog no. 70R-8358

A synthetic peptide for use as a blocking control in assays to test for specificity of ABCC1 antibody, catalog no. 70R-6981

A synthetic peptide for use as a blocking control in assays to test for specificity of PRKACA antibody, catalog no. 70R-4594

A synthetic peptide for use as a blocking control in assays to test for specificity of ACADS antibody, catalog no. 70R-2485

A synthetic peptide for use as a blocking control in assays to test for specificity of Tbcb antibody, catalog no. 70R-9129

A synthetic peptide for use as a blocking control in assays to test for specificity of CCBP2 antibody, catalog no. 70R-7846

A synthetic peptide for use as a blocking control in assays to test for specificity of TGFBI antibody, catalog no. 70R-1826

Glucagon (Human) is a recombinant peptide hormone, which is synthesized to mimic the natural glucagon produced by alpha cells in the pancreas. This biopharmaceutical is derived from a DNA recombinant technology source, offering a high level of purity and consistency. Its mode of action involves binding to glucagon receptors on liver cells, stimulating glycogenolysis and gluconeogenesis. This results in the rapid conversion of glycogen into glucose, thereby raising blood sugar levels.Glucagon (Human) is primarily utilized in the treatment of severe hypoglycemia, especially in diabetic patients unable to consume oral glucose due to unconsciousness or confusion. Its application is critical in acute settings where rapid intervention is necessary to prevent neurological damage from prolonged hypoglycemia. Additionally, the research and clinical use of glucagon extend to investigating its potential in counteracting beta-blocker and calcium channel blocker overdoses, where it acts to increase cardiac output. This hormone's pharmaceutical development has provided a crucial tool in both emergency response and broader therapeutic research contexts.

A synthetic peptide for use as a blocking control in assays to test for specificity of FBLN1 antibody, catalog no. 70R-5356

A synthetic peptide for use as a blocking control in assays to test for specificity of ZBTB3 antibody, catalog no. 70R-8377

Sarafotoxin S6b, sourced from the venom of the Atractaspis engaddensis snake family, is one of four (S6a-d) isopeptides of the Sarafotoxins. This product is a synthetically produced toxin, containing disulfide bonds between Cys1-Cys15 and Cys3-Cys11.Due to their structural and functional homology to the endothelin peptides, Sarafotoxins can enhance vasoconstriction through stimulating the class A G-protein-coupled, endothelin ETA and ETB receptors. This in turn leads to left ventricular dysfunction and bronchoconstriction.
As the most potent Sarafotoxin, sarafotoxin S6b binds to both ETA and ETB receptors with a similar affinity to Endothelin-1. This is evident as when given to mice intravenously, sarafotoxin S6b caused cardiac arrest and death in mice almost immediately. Additional characteristics of S6b is its matrix metalloproteinase inhibitory activity due to it exhibiting a fold which is also found in the core region of tissue inhibitors of metalloproteinases (TIMPs).
Sarafotoxin S6b can be used as a pharmacological reagent to study the interactions of Endothelins and their corresponding receptors. This product is available as a 0.1mg vial.

A synthetic peptide for use as a blocking control in assays to test for specificity of PQLC1 antibody, catalog no. 70R-7332

A synthetic peptide for use as a blocking control in assays to test for specificity of OAS1 antibody, catalog no. 70R-5884

A synthetic peptide for use as a blocking control in assays to test for specificity of C1orf166 antibody, catalog no. 70R-5998

A synthetic peptide for use as a blocking control in assays to test for specificity of AKR1C2 antibody, catalog no. 70R-4046

A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf68 antibody, catalog no. 70R-4309

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP3A43 antibody, catalog no. 70R-7258

A synthetic peptide for use as a blocking control in assays to test for specificity of LANCL2 antibody, catalog no. 70R-2713

A synthetic peptide for use as a blocking control in assays to test for specificity of FLJ44894 antibody, catalog no. 70R-8899

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Please enquire for more information about Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)-fluoromethylketone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Extraordinary strength of the streptavidin-biotin interaction allows for efficient capturing of even highly dilute targets; however, it makes recovery of proteins from affinity resins challenging. Conventional methods to elute biotinylated proteins from immobilized avidin include the following: (i) denaturation of streptavidin by boiling the resin in a denaturing buffer that may include high concentrations of chaotropic salts, (ii) trypsin digestion of proteins while they are bound to the resin, or (iii) elution of proteins with excess free biotin. These protocols can co-elute contaminant proteins by releasing nonspecifically bound proteins and/or naturally biotinylated proteins concurrently with labeled proteins. In addition, some of these methods can cause elution of high levels of resin-based peptides along with the proteins of interest, resulting in further sample contamination.
Disulfide Biotin Azide probe eliminates a major limitation of the streptavidin-biotin affinity purification. This reagent contains a biotin moiety linked to an azide moiety through a spacer arm containing a cleavable disulfide linker. Captured biomolecules can be efficiently released under mild conditions (50 mM dithiothreitol, 10 mM 2-mercaptoethanol or 1% sodium borohydride) and the small molecular fragment (188.25 Da) left on the labeled protein following cleavage. These features make the cleavable probe especially attractive for use in biomolecular labeling and proteomic studies.

Catalogue peptide; min. 95% purity